Inhaled ciprofloxacin for chronic airways infections caused by Pseudomonas aeruginosa.

about

Ciprofloxacin DPI in non-cystic fibrosis bronchiectasis: a Phase II randomized study.Efficacy and safety of long-term inhaled antibiotic for patients with noncystic fibrosis bronchiectasis: a meta-analysis.

P2860

Q42270022-E7BB67C2-6E0C-406A-80BA-B502F8A8879A Q51428053-B0037048-94E7-4347-84D0-DE09728CF8EA

P2860

Inhaled ciprofloxacin for chronic airways infections caused by Pseudomonas aeruginosa.

Item

http://www.wikidata.org/entity/Q38068608

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Inhaled ciprofloxacin for chronic airways infections caused by Pseudomonas aeruginosa.

@en

type

Item

label

Inhaled ciprofloxacin for chronic airways infections caused by Pseudomonas aeruginosa.

@en

prefLabel

Inhaled ciprofloxacin for chronic airways infections caused by Pseudomonas aeruginosa.

@en

P1476

Inhaled ciprofloxacin for chronic airways infections caused by Pseudomonas aeruginosa.

@en

P2093

Sabina Antonela Antoniu

http://www.w3.org/2001/XMLSchema#string

P2860

Antimicrobial safety: focus on fluoroquinolones

Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis.

Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease.

Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis

Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB-oprM genes.

Management of refractory Pseudomonas aeruginosa infection in cystic fibrosis

Ciprofloxacin safety in paediatrics: a systematic review.

Targeting mechanisms of Pseudomonas aeruginosa pathogenesis.

Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health.

Evolution of Pseudomonas aeruginosa type III secretion in cystic fibrosis: a paradigm of chronic infection

P304

1439-1446

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERI.12.136

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23253321

http://www.w3.org/2001/XMLSchema#string

P921

Pseudomonas aeruginosa

Inhaled ciprofloxacin for chronic airways infections caused by Pseudomonas aeruginosa.

about

P2860

P2860

Inhaled ciprofloxacin for chronic airways infections caused by Pseudomonas aeruginosa.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921